IDH1 and glioblastoma: Another innovation in our study was that a nomogram that combined the risk signature and clinicopathological factors (IDH1 status, age and experience of radiotherapy or chemotherapy) was established for predicting 1‐, 3‐ and 5‐year survival rate of GBM patients.